PTUPB is a novel COX-2 and sEH dual inhibitor [31], and we demonstrated that PTUPB could suppress PF [30], acute lung injury [33], nonalcoholic fatty liver disease [34], and sepsis [35]. Here, PTGS2 is linked to metabolic dysfunction-associated steatotic liver disease.